The global Breast Cancer Drugs market size is expected to be worth around US$ 40.4 billion by 2030, according to a new report by Vision Research Reports.
The global Breast Cancer Drugs market size was valued at US$ 17.98 billion in 2020 and is anticipated to grow at a CAGR of 11.7% during forecast period 2021 to 2030.
Growth Factors
Early detection, increase in awareness, and incidence of breast cancer are some of the key trends stoking market growth.
Global breast cancer drugs market is expected to grow lucratively as many players focus majorly on R&D of innovative treatments. They engage in extensive research to develop novel drugs for the treatment of the disease to gain a higher market share. There exists a growing pressure and need for novel therapies and treatment due to rapidly accelerating prevalence of diseases. The strong pipeline is expected to provide new and effective treatment options and improved outcomes than existing therapies.
With advancements in drug delivery systems, various target specific therapies have been customized and designed as a carrier to infuse the therapeutic agent to the target site. Carriers for inducing target therapy include modified anticancer agent’s specific to molecular-recognition-element, anticancer peptides, and nanoparticle-based anticancer drugs. For instance, HER2/neu protein is usually given in combination with other anti-cancer drugs in targeted therapy.
Report Highlights
HER2 inhibitors is identified as the most lucrative segment of the breast cancer drugs market. Growing incidence of HER2 positive breast cancer is the major factor attributed to the growth of this segment. According to an article published by F. Hoffman La Roche Ltd in 2013, it was estimated that approximately one in five women diagnosed with breast tumor would have HER2 positive cancer. Moreover, rapidly growing demand from emerging markets such as Asia Pacific and Latin America, is expected to further drive the growth during the forecast period.
CDK 4/6 inhibitor is expected to be the fastest growing segment over the forecast period. These drugs are expected to improve the survival rate in patients with metastatic breast cancer. Moreover, commercialization of novel drugs, such as Kisqali by Novartis AG and Verzenio by Eli Lilly and Company is expected to propel growth of the segment in the forthcoming years.
Increasing awareness and presence of established R&D infrastructure are among the key factors contributing to growth of the market in North America. Moreover, presence of key players such as Pfizer, Inc.; Merck & Co., Inc.; Celgene Corporation; and AbbVie, Inc. in the region is expected to drive the growth. Rising awareness about the benefits of early detection of cancer has driven the U.S.-based companies to make considerable investments in the development of targeted therapy drugs.
Asia Pacific is anticipated to expand at the fastest CAGR of 11.9% during the forecast period. Rapid growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing and R&D in this region. Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease is anticipated to propel the regional growth. For instance, Wacoal Corp. runs the Pink Ribbon Fitting Campaign and donates funds to Japan Society of Breast Health, J. POSH, and Japan Cancer Society (Smile Fund) on behalf of customers.
Key Players
F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.
Market Segmentation
Type Outlook
HER2 Inhibitors
Mitotic Inhibitors
Anti-metabolites
Aromatase Inhibitors
CDK 4/6 Inhibitors
Hormonal Receptor
Regional Outlook
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Middle East & Africa
South Africa
The Breast Cancer Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Breast Cancer Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Breast Cancer Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Breast Cancer Drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Breast Cancer Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Breast Cancer Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Breast Cancer Drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Breast Cancer Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Breast Cancer Drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Breast Cancer Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Breast Cancer Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Breast Cancer Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Breast Cancer Drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Breast Cancer Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Breast Cancer Drugs market. These factors have benefited the growth of the global market for Breast Cancer Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Breast Cancer Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Breast Cancer Drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
To strategically profile the key players and comprehensively analyze their growth strategies.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Breast Cancer Drugs Market, By Type
7.1. Breast Cancer Drugs Market, By Type, 2020-2028
7.1.1. HER2 Inhibitors
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Mitotic Inhibitors
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Anti-metabolites
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Aromatase Inhibitors
7.1.4.1. Market Revenue and Forecast (2016-2028)
7.1.5. CDK 4/6 Inhibitors
7.1.5.1. Market Revenue and Forecast (2016-2028)
7.1.6. Hormonal Receptor
7.1.6.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Breast Cancer Drugs Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, By Type (2016-2028)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, By Type (2016-2028)
8.2. Europe
8.2.1. Market Revenue and Forecast, By Type (2016-2028)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, By Type (2016-2028)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, By Type (2016-2028)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, By Type (2016-2028)
8.3. APAC
8.3.1. Market Revenue and Forecast, By Type (2016-2028)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, By Type (2016-2028)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, By Type (2016-2028)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, By Type (2016-2028)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, By Type (2016-2028)
8.4. MEA
8.4.1. Market Revenue and Forecast, By Type (2016-2028)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, By Type (2016-2028)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, By Type (2016-2028)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, By Type (2016-2028)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, By Type (2016-2028)
8.5. Latin America
8.5.1. Market Revenue and Forecast, By Type (2016-2028)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, By Type (2016-2028)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, By Type (2016-2028)
Chapter 9. Company Profiles
9.1. F. Hoffmann-La Roche Ltd.
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Novartis AG
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. AbbVie, Inc.
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. AstraZeneca
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Eli Lilly and Company
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Celgene Corporation
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Biocon
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. Merck & Co., Inc.
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. Genzyme Corporation
9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
9.10. Janssen Global services LLC
9.10.1. Company Overview
9.10.2. Product Offerings
9.10.3. Financial Performance
9.10.4. Recent Initiatives
9.11. MacroGenics, Inc.
9.11.1. Company Overview
9.11.2. Product Offerings
9.11.3. Financial Performance
9.11.4. Recent Initiatives
9.12. Celldex Therapeutics
9.12.1. Company Overview
9.12.2. Product Offerings
9.12.3. Financial Performance
9.12.4. Recent Initiatives
9.13. Onyx Pharmaceuticals Inc.
9.13.1. Company Overview
9.13.2. Product Offerings
9.13.3. Financial Performance
9.13.4. Recent Initiatives
9.14. BioNumerik Pharmaceuticals, Inc
9.14.1. Company Overview
9.14.2. Product Offerings
9.14.3. Financial Performance
9.14.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
Glossary of Terms